Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.

Cabral-Miranda, Gustavo; Heath, Matthew D; Gomes, Ariane C; Mohsen, Mona; Montoya-Diaz, Eduardo; Salman, Ahmed M; Atcheson, Erwan; Skinner, Murray A; Kramer, Matthias F; Reyes-Sandoval, Arturo; Bachmann, Martin (2017). Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines, 5(4) MDPI 10.3390/vaccines5040032

[img]
Preview
Text
vaccines-05-00032-v2.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (3MB) | Preview

Microcrystalline Tyrosine (MCT®) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria. To this end, we formulated the circumsporozoite protein (CSP) of P. vivax in MCT and compared the induced immune responses to CSP formulated in PBS or Alum. Both MCT and Alum strongly increased immunogenicity of CSP compared to PBS in both C57BL/6 and BALB/c mice. Challenge studies in mice using a chimeric P. bergei expressing CSP of P. vivax demonstrated clinically improved symptoms of malaria with CSP formulated in both MCT and Alum; protection was, however, more pronounced if CSP was formulated in MCT. Hence, MCT may be an attractive biodegradable adjuvant useful for the development of novel prophylactic vaccines.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie

UniBE Contributor:

Mohsen, Mona and Bachmann, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2076-393X

Publisher:

MDPI

Language:

English

Submitter:

Eveline Messerli

Date Deposited:

13 Mar 2018 11:32

Last Modified:

26 Oct 2019 07:26

Publisher DOI:

10.3390/vaccines5040032

PubMed ID:

28953265

Uncontrolled Keywords:

MCT adjuvant malaria vaccine

BORIS DOI:

10.7892/boris.110608

URI:

https://boris.unibe.ch/id/eprint/110608

Actions (login required)

Edit item Edit item
Provide Feedback